{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-26-000048","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-06-17T12:03:10+00:00","discovered_at":"2026-06-17T12:05:00.428960+00:00","generated_at":"2026-06-17T12:05:24.337658+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC","bullets":["100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.","Complete responses rarely observed (0-8%) in metastatic pancreatic cancer; all 3 patients are MSS/MMR-p, historically refractory to immunotherapy.","Two patients maintained complete responses ≥8 months; one ongoing >13 months with persistent mKRAS-specific T cells.","Elicio plans Phase 1 study in first-line metastatic mKRAS PDAC combining ELI-002 7P with chemotherapy and anti-PD-1, subject to funding.","Virtual KOL event June 24, 2026, to discuss observations with UCLA and University of Miami oncologists."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-26-000048","json":"https://secwatch.observer/filing/0001601485-26-000048.json","markdown":"https://secwatch.observer/filing/0001601485-26-000048.md","text":"https://secwatch.observer/filing/0001601485-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/0001601485-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/angn-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:05:24.337658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}